8-KOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Feb 1, 2006)

Filed February 1, 2006For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 1, 2006, to report on a significant equity financing event. The company entered into an underwriting agreement on January 31, 2006, to issue and sell approximately 5.1 million shares of its common stock. This offering, priced at $13.00 per share, is expected to generate net proceeds of around $62.3 million for Alnylam after accounting for underwriting discounts and offering expenses. The filing also indicates Alnylam granted the underwriters an option to purchase an additional 767,394 shares to cover potential over-allotments. This capital raise is crucial for a biotechnology company like Alnylam, providing essential funding to advance its research and development pipeline, potentially fueling future drug discovery and clinical trials. Investors should note this as a positive development for bolstering the company's financial resources.

Key Highlights

  • 1Alnylam Pharmaceuticals, Inc. announced an equity offering of 5,115,961 shares of common stock.
  • 2The offering was priced at $13.00 per share.
  • 3The company expects to receive approximately $62.3 million in net proceeds from the offering.
  • 4An over-allotment option for up to an additional 767,394 shares was granted to the underwriters.
  • 5The shares were registered under a Form S-3 registration statement filed previously.
  • 6The underwriting agreement was dated January 31, 2006.
  • 7Key underwriters include Morgan Stanley & Co. Incorporated, Banc of America Securities LLC, and others.

Frequently Asked Questions

This 8-K filing reports on a material event for Alnylam Pharmaceuticals, Inc.: the execution of an underwriting agreement for a public offering of its common stock. It provides details on the number of shares offered, the price per share, and the expected net proceeds to the company.

Alnylam Pharmaceuticals, Inc. is expected to raise approximately $62.3 million in net proceeds from the sale of 5,115,961 shares of its common stock, after deducting underwriting discounts, commissions, and estimated offering expenses.

The over-allotment option, also known as a greenshoe option, allows the underwriters to purchase up to an additional 767,394 shares at the offering price. This is typically granted to help stabilize the stock price in the aftermarket and to meet higher-than-expected demand. If exercised, it would result in Alnylam selling more shares and receiving additional proceeds.

The shares offered were registered pursuant to a Registration Statement on Form S-3 (File No. 333-129905) filed on November 23, 2005, as amended, and a related Registration Statement on Form S-3 (File No. 333-131233) filed on January 23, 2006, under the Securities Act of 1933.